Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy
Shots:
- The FIREFISH Part 2 study involves assessing risdiplam in 41 infants aged 1-7mos. with Type 1 SMA treated for 24mos.- followed by an open-label extension
- The study met its 1EPs with 29% of infants sitting without support for 5sec by 12mos. as assessed by the Gross Motor Scale of BSID-III- 43.9% infants were able to hold their head upright- 31.7% were able to roll to the side- 4.9% infants were able to stand with support as measured by HINE-2. In exploratory endpoint- 95% were alive @12mos. maintained the ability to swallow and 89% were able to feed orally
- Risdiplam is an SMN2 splicing modifier- designed to durably increase and sustain SMN protein levels both throughout the CNS and PNS and has received the FDA’s ODD in 2017- EMA’s PRIME designation in 2018 and FDA’s PR in Nov’2019 with its anticipated decision on approval by Aug 24- 2020
Click here to read full press release/ article
Ref: Roche | Image: Roche
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com